Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population. Immunotherapy with passive or active immunizations targeting amyloid beta (Aβ) build-up in the brain may provide a possible treatment option and may help prevent AD from progressing. A number of passive immunizations with anti-Aβ42 antibodies are in different phases of clinical trials. One active immunization approach, AN-1792, was stopped after the development of autoimmune encephalitis in 6% of patients and a second one, CAD106, in which a small Aβ epitope is used, is currently in safety and tolerability studies. Besides active immunizations with proteins or peptides, active immunizations using DNA which codes for the protein against which the immune response will be directed, so called genetic immunizations, provide additional safety as the immune response in DNA immunizations differs quantitatively and qualitatively from the response elicited by peptide immunizations. We summarize in this review our data using DNA Aβ42 immunizations in mouse models and discuss the results together with the results presented by many other groups working on a DNA vaccine as treatment option for AD.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalTranslational Neuroscience
Volume3
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Immunotherapy
Immunization
Alzheimer Disease
Vaccination
Passive Immunization
DNA
Safety
Peptides
DNA Vaccines
Amyloid
Neurodegenerative Diseases
Dementia
Epitopes
Anti-Idiotypic Antibodies
Proteins
Clinical Trials
Brain
Therapeutics
Population

Keywords

  • Alzheimer's disease
  • Amyloid beta
  • Immunotherapy
  • Vaccination

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. / Lambracht-Washington, Doris; Rosenberg, Roger N.

In: Translational Neuroscience, Vol. 3, No. 4, 12.2012, p. 307-313.

Research output: Contribution to journalArticle

@article{e692dbbcba894f0aa366073934cecf62,
title = "Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease",
abstract = "As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population. Immunotherapy with passive or active immunizations targeting amyloid beta (Aβ) build-up in the brain may provide a possible treatment option and may help prevent AD from progressing. A number of passive immunizations with anti-Aβ42 antibodies are in different phases of clinical trials. One active immunization approach, AN-1792, was stopped after the development of autoimmune encephalitis in 6{\%} of patients and a second one, CAD106, in which a small Aβ epitope is used, is currently in safety and tolerability studies. Besides active immunizations with proteins or peptides, active immunizations using DNA which codes for the protein against which the immune response will be directed, so called genetic immunizations, provide additional safety as the immune response in DNA immunizations differs quantitatively and qualitatively from the response elicited by peptide immunizations. We summarize in this review our data using DNA Aβ42 immunizations in mouse models and discuss the results together with the results presented by many other groups working on a DNA vaccine as treatment option for AD.",
keywords = "Alzheimer's disease, Amyloid beta, Immunotherapy, Vaccination",
author = "Doris Lambracht-Washington and Rosenberg, {Roger N.}",
year = "2012",
month = "12",
doi = "10.2478/s13380-012-0037-6",
language = "English (US)",
volume = "3",
pages = "307--313",
journal = "Translational Neuroscience",
issn = "2081-3856",
publisher = "de Gruyter",
number = "4",

}

TY - JOUR

T1 - Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

AU - Lambracht-Washington, Doris

AU - Rosenberg, Roger N.

PY - 2012/12

Y1 - 2012/12

N2 - As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population. Immunotherapy with passive or active immunizations targeting amyloid beta (Aβ) build-up in the brain may provide a possible treatment option and may help prevent AD from progressing. A number of passive immunizations with anti-Aβ42 antibodies are in different phases of clinical trials. One active immunization approach, AN-1792, was stopped after the development of autoimmune encephalitis in 6% of patients and a second one, CAD106, in which a small Aβ epitope is used, is currently in safety and tolerability studies. Besides active immunizations with proteins or peptides, active immunizations using DNA which codes for the protein against which the immune response will be directed, so called genetic immunizations, provide additional safety as the immune response in DNA immunizations differs quantitatively and qualitatively from the response elicited by peptide immunizations. We summarize in this review our data using DNA Aβ42 immunizations in mouse models and discuss the results together with the results presented by many other groups working on a DNA vaccine as treatment option for AD.

AB - As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population. Immunotherapy with passive or active immunizations targeting amyloid beta (Aβ) build-up in the brain may provide a possible treatment option and may help prevent AD from progressing. A number of passive immunizations with anti-Aβ42 antibodies are in different phases of clinical trials. One active immunization approach, AN-1792, was stopped after the development of autoimmune encephalitis in 6% of patients and a second one, CAD106, in which a small Aβ epitope is used, is currently in safety and tolerability studies. Besides active immunizations with proteins or peptides, active immunizations using DNA which codes for the protein against which the immune response will be directed, so called genetic immunizations, provide additional safety as the immune response in DNA immunizations differs quantitatively and qualitatively from the response elicited by peptide immunizations. We summarize in this review our data using DNA Aβ42 immunizations in mouse models and discuss the results together with the results presented by many other groups working on a DNA vaccine as treatment option for AD.

KW - Alzheimer's disease

KW - Amyloid beta

KW - Immunotherapy

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84871417422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871417422&partnerID=8YFLogxK

U2 - 10.2478/s13380-012-0037-6

DO - 10.2478/s13380-012-0037-6

M3 - Article

C2 - 23741624

AN - SCOPUS:84871417422

VL - 3

SP - 307

EP - 313

JO - Translational Neuroscience

JF - Translational Neuroscience

SN - 2081-3856

IS - 4

ER -